Navigation Links
NovaBay Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2008 Financial Results
Date:4/1/2009

logical efficacy in-vivo in treating subcutaneous dermatophyte infections based on an established animal model. Importantly, these data combined with the past preclinical work that showed NVC-422 kills P. Acne, in the follicle, strongly suggest that NVC-422 may be a potent and well-tolerated treatment for acne and other numerous serious skin infections.

  • Hospital infections: In May 2008, NovaBay successfully completed a Phase I trial that showed NVC-422 was well tolerated in the bladder as a lavage solution for catheterized patients. In November 2008, the company commenced patient enrollment in a Phase II exploratory study of hospitalized patients who are catheterized and have bacteriuria. Data from this ongoing study, which is expected later this year, if positive, will provide support for future development plans for catheter-associated urinary tract infections, the most common hospital-acquired infection.

  • Respiratory infections: In May 2008, NovaBay completed its Phase IIa study of NVC-422 for nasal decolonization of Staphylococcus aureus, including MRSA (Methicillin Resistant Staphylococcus Aureus). In this study, two concentrations of a prototype nasal spray formulation of NVC-422 were tested to decolonize the lower nasal passages and were both found to be well tolerated. Based on a statistical analysis the higher dose treatment group provided consistent S. aureus reduction below the baseline score throughout the treatment period.

  • Intellectual property: NovaBay continues to solidify and expand its proprietary position in the Aganocide compounds and related antimicrobial technologies. NovaBay's key composition of matter patent for Aganocide compounds, including NVC-422, was issued by the U.S. Patent and Trademark Office
    '/>"/>

SOURCE NovaBay Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. NovaBay and Galderma Enter Into Global Agreement to Develop and Commercialize NovaBays Novel Aganocide Drugs for Major Dermatological Conditions
2. NovaBay Pharmaceuticals Prices Initial Public Offering of Common Stock
3. Alseres Pharmaceuticals, Inc. Complies with NASDAQ Rule Regarding Recently Filed 10-K
4. Angiotech Pharmaceuticals, Inc. announces License Agreement with Baxter International Inc.
5. Trubion Pharmaceuticals, Inc. Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Systemic Lupus Erythematosus (SLE)
6. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results
7. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2008 Financial Results
8. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2008 Financial Results on Friday, March 13, 2009 at 8:30am EDT
9. Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008
10. Angiotech Pharmaceuticals, Inc. announces new Senior Secured Term Loan and Credit Facilities
11. Alseres Pharmaceuticals, Inc. Announces $1 Million Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... by researchers at the USC Viterbi School of ... 3-D microfluidic system quickly and cheaply by simply ... Microfluidic systems are used in many fields including ... volumes of fluids for use in applications such ... diagnostic testing, and synthetic chemistry. Traditionally, microfluidic devices ...
(Date:9/22/2014)... University of Manchester have generated a new star-shaped molecule made ... its kind ever created. , Known as a ... one for over a quarter of a century and the ... . , Consisting of two molecular triangles, entwined about ... molecules are tiny each triangle is 114 atoms in ...
(Date:9/22/2014)... September 22, 2014 Lawrence Livermore ... John DeGioia on Friday renewed their institutional commitment ... additional five years to expand the collaborative work ... and global climate, energy and environmental sciences. , ... MOU originally signed in December 2009 and is ...
(Date:9/22/2014)... NY (PRWEB) September 22, 2014 Topical ... helping those in pain end their suffering, restoring hope ... healthcare model. This is only possible because of the ... and healing cream technology a reality. , The ... Rhinebeck, NY, by Lou Paradise (president, chief of research, ...
Breaking Biology Technology:Lego-like modular components make building 3-D 'labs-on-a-chip' a snap 2Lego-like modular components make building 3-D 'labs-on-a-chip' a snap 3Lego-like modular components make building 3-D 'labs-on-a-chip' a snap 4Lego-like modular components make building 3-D 'labs-on-a-chip' a snap 5Lawrence Livermore Renews Pact with Georgetown University to Expand Research and Education in Science and Policy 2Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 2Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 3Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 4Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 5Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 6
... 18 Caliper Life,Sciences, Inc. (Nasdaq: CALP ... Global Life Sciences Conference in New York City, ... 3:30 p.m. EDT. Kevin Hrusovsky, President,and CEO of ... company,s business.,The audio-only webcast can be accessed at, ...
... Cellectar, Inc., a,privately-held radiopharmaceuticals company that designs and ... today announced the,appointment of Charles C. Harwood, Jr., ... 55, is a Healthcare Industry Advisor for Avista ... working with Avista,Mr. Harwood was President and Chief ...
... 18 CJPS Enterprises, LLC, the,operator of the ... schedule available to Michigan companies interested in learning,about ... healthcare,industry. CJPS Enterprises, LLC (http://www.CJPS-Enterprises.com ) was ... (MEDC) as,part of the Life Sciences Pipeline initiative, ...
Cached Biology Technology:Charles C. Harwood, Jr., Joins Cellectar, Inc.'s Board of Directors 2The Michigan Life Sciences Pipeline Announces New Best Practices Seminars Tailored to Michigan Businesses 2
(Date:9/22/2014)... NEW YORK CITY (September 22, 2014)The Brain ... the award of NARSAD Young Investigator ... to 200 of the world,s most promising ... grants for groundbreaking neurobiological research will seek ... prevention strategies for psychiatric disorders that affect ...
(Date:9/22/2014)... If you,re overweight, you may be at greater ... cardiovascular disease and cancer, according to a new ... that psychological stress can trigger biological responses similar ... inflammation. While normal inflammation is an important part ... contribute to chronic and life-threatening diseases. , ...
(Date:9/21/2014)... Mothers of children with autism are significantly less likely ... pregnancies than the mothers of children who are developing ... MIND Institute has found. , Low iron intake was ... the child if the mother was 35 or older ... she suffered from metabolic conditions such as obesity hypertension ...
Breaking Biology News(10 mins):Brain & Behavior Research Foundation awards 200 NARSAD Young Investigator grants 2Obesity and stress pack a double hit for health 2Mothers of children with autism less likely to have taken iron supplements 2
... received a $3.3 million contract from the U.S. Defense Advanced ... be so soft and squishy that they will be able ... morph back into something 10 times larger, and ultimately biodegrade. ... conduct dangerous or difficult operations are clear, and the U.S. ...
... essential hypertension also develop diabetes and other complications in ... discovered a common molecular mechanism in a strain of ... in mammals. , The bioengineering researchers at UC San ... drug developed for unrelated purposes in humans was effective ...
... Crohn,s disease researchers has combined data from three ... associated with the inflammatory bowel disorder, bringing the ... Several of these are involved with the immune ... that disruptions in a process called autophagy may ...
Cached Biology News:Tufts to develop morphing 'chemical robots' 2Tufts to develop morphing 'chemical robots' 3A single mechanism for hypertension, insulin resistance and immune suppression 2A single mechanism for hypertension, insulin resistance and immune suppression 3A single mechanism for hypertension, insulin resistance and immune suppression 4International team identifies 21 new genetic risk factors for Crohn's disease 2
... cDNA Library Panels were designed for full-length ... of PCRs to identify the desired cDNA ... in a 96-well "Master Plate," where each ... Having identified the positive well(s) by gel ...
... Analysis Note: Evaluated for its amino acid ... of amino acids Ala, Asp, Gly, Ile, Lys, ... Ser, Tyr. Preparation Unit Definition: One unit will ... 1.0 ml of water (1 cm light path). ...
... use as a carrier in ... Physical form: Solution in 10 ... 1 mM EDTA Preparation Note: ... Concentration: 10 mg/mL ...
... Cleland’s Reagent, Immobilized White solid. ... form of DTT on polyacrylamide resin with applications ... 233153 , 233156 , and ... no soluble components are added to the system. ...
Biology Products: